Scynexis' (SCYX) Treatment of Invasive Aspergillus Infections Granted Orphan Drug Status by FDA
Go back to Scynexis' (SCYX) Treatment of Invasive Aspergillus Infections Granted Orphan Drug Status by FDASCYNEXIS (NASDAQ: SCYX) | Delayed: 1.47 +0.05 (3.52%) | |||||
---|---|---|---|---|---|---|
Previous Close | $1.42 | 52 Week High | $7.29 | |||
Open | $1.42 | 52 Week Low | $1.74 | |||
Day High | $1.52 | P/E | N/A | |||
Day Low | $1.42 | EPS | $0.00 | |||
Volume | 184,056 |